Prof. Matthew Kiernan

Chief Executive Officer and Institute Director, Neuroscience Research Australia Scientia Professor of Neuroscience at the University of New South Wales, Sydney, Australia Senior Staff Specialist in Neurology, South Eastern Sydney Local Health District

This video delves into the complexities of clinical trials and treatment for dementia. Professor Dr. Matthew Kiernan discusses the limitations of current trial models, the need for personalized biomarkers, and the challenges of using a one-size-fits-all approach.

Learn more about Alzheimer’s Disease and Dementia here

Published 12.11.2024
Permissions
Published 12.11.2024
Permissions

Related content

image Image A multi-arm, multi-stage platform trial illustration
A multi-arm, multi-stage platform trial illustration
29.04.2025 Alzheimer’s Disease
image Image Drug Delivery Systems to the Brain
Drug Delivery Systems to the Brain

Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).

29.04.2025 Alzheimer’s Disease
image Image From One-Size-Fits-All to Precision Medicine
From One-Size-Fits-All to Precision Medicine

The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.

29.04.2025 Alzheimer’s Disease